Pioneering Safe and Effective RNA Cancer Therapy

Advanced AI technology enables us to develop a special class of compound that’s designed to precisely target and treat diseases at the genetic level.

RNA Therapeutics Platform

Unique drug design blocks pathogenic RNAs in multiple diseases, including cancer

Next- Generation Chemistry

Proprietary chemistry yields smaller, more specific, less toxic drugs

Disease-specific drug Delivery

Targeted delivery agent carries modified RNA drugs into disease cells, reducing toxicity to normal cells

What we do

Bound Therapeutics is a pioneering biotechnology firm dedicated to the development of RNA-based therapies targeting rare and refractory diseases, with a primary focus on oncology. Our proprietary platform, Magic Bullet Designer (MBD), utilizes advanced artificial intelligence and machine learning algorithms to optimize the tissue-specific delivery of RNA therapeutics, thereby enhancing precision and therapeutic efficacy.

Currently in the preclinical stage, our pipeline encompasses novel treatments for aggressive malignancies and genetic disorders, positioning Bound Therapeutics at the forefront of next-generation RNA therapeutics.

 
Play Video

About Us

Bound Therapeutics was founded in 2015 by a team of renowned scientists and biopharmaceutical leaders driven to revolutionize cancer treatment through innovative RNA therapeutics. Combining decades of expertise, the company developed a proprietary AI-optimized nanocomplex platform to overcome traditional pharmaceutical limitations and address unmet medical needs.

State-Of- The-Art AI-Driven Technology

The proprietary Magic Bullet Designer (MBD) AI performs de novo peptide ligand design for tissue-targeted drug delivery.

Partnership

Bound Therapeutics Strives to Improve Lifespan and Quality of Life

Our Leaders

Bound Therapeutics is led by a seasoned team of biotech veterans with deep expertise in AI-driven drug discovery, nanoparticle engineering, oncology research, and successful pharmaceutical commercialization. 

Chief Business Advisor
Phong Tran
PhD, Co-Founder, CSO
Eric Wickstrom
PhD, Co-Founder, COO
Yuanyuan Jin
MS, CTO
Jason Mazzaroth
MBA, Strategic Advisor
Masatomo Sakairi

Press Release​

June 14, 2019

RNA Blockade to Treat Triple Negative Breast Cancer

News
September 10, 2018

Bound Therapeutics is selected as a finalist in the UC Science Center QED proof-of-concept program

News
October 30, 2017

Bound Therapeutics formed strategic alliance with Bio-Synthesis, Inc. to jointly develop bridged nucleic acid (BNA)-based RNA therapeutics

News